Medical 21, Inc.

Through three quarters, we've seen increased investment across all Medtech and Healthtech verticals, and many new financing rounds across the LSI Alumni community. During Q3 this momentum continued to grow as we saw the LSI Alumni raise nearly $900M across 55+ deals in Q3 alone. Throughout 2024, LSI Alumni have collectively raised over $2 billion in total capital through 120+ deals. These achievements reflect not just the success of the LSI Alumni but also the momentum and innovation driving the Medtech industry as a whole. Congratulations to all those contributing to these milestones, pushing the boundaries of what's possible, and ultimately advancing patient care. There were over 50 LSI Alumni deals in Q3, so I can’t list them all, but here are a few call-outs: - Kneevoice Inc. (Gustavo De Greiff) // $1.25M Seed - Prana Thoracic (Joanna Nathan) // $3M Series A Extension - CorFlow (Paul Mead) // €44M Series B - NanoHive Medical (Patrick O.) // $7M Series C - WISE SpA (Luca Ravagnan) // €25M Series D - Magenta Medical Ltd. (David Israeli, MD) // $105M Later Stage View our spreadsheet with all the companies, deals, investors & more: https://lnkd.in/djUYnsMK

With over 50 years of Medtech innovation and 7 IPOs under his belt, Manny Villafa?a, Ph.D.Sc. has revolutionized the medical device industry time and time again. At LSI USA ‘24, Manny Villafa?a, Founder, Chairman, & CEO of Medical 21, Inc., sat down with Omar M. Khateeb, Founder of Khateeb & Co. and host of the State of Medtech podcast, for an in-depth interview that dove into the pivotal moments of his career and what ultimately led him to his latest venture, Medical 21. Medical 21 is on a mission to revolutionize coronary artery bypass graft (CABG) surgery by developing a synthetic graft that could eliminate the need for harvesting blood vessels from the patient’s body. This innovation aims to overcome the limitations of traditional bypass surgery, such as complications from vessel harvesting, increased surgical time, and patient discomfort. The synthetic graft technology is designed to replicate the function of natural blood vessels while ensuring biocompatibility and durability. Most recently, Medical 21 announced a $2.5M raise to accelerate the development of its technology, bringing it one step closer to transforming the standard of care for CABG surgery. Catch the full interview on our website and YouTube channel to hear more from Manny Villafa?a and Omar M. Khateeb.

There have been no initial public offerings in the state since 2021, but Anteris and Medical 21 could change that.

The top MSP Life Science real estate transactions last year. Our Q1 2024 newsletter is out now: https://lnkd.in/d7UHY_kH

For this week’s Road to Dana Point, I’m coming to you live from Medical Alley in Minneapolis, MN to share some updates from a visit one of the most well-known entrepreneurs in Medtech. In the midst of our LSI USA prep, I got to visit the new, expanded facilities of Medical 21, Inc. with founder and good friend, Manny Villafa?a. They’ll be back at LSI USA ‘24 with some more exciting updates about the progress of their artificial graft technology. Staying in an adjacent space, I’m thrilled to congratulate Edwards Lifesciences on making history as the first to earn US FDA approval for a transcatheter therapy to treat tricuspid regurgitation. Timely announcement, as we’re looking forward to hearing from Bernard Zovighian, CEO of Edwards in his keynote with Paul LaViolette, and from Donald E Bobo Jr, Corporate VP at Edwards who will speak on a new panel on Innovation in Structural Heart. We’re just 6 short weeks away from gathering over 1,200+ Medtech and Healthtech leaders at LSI USA '24 in Dana Point, CA, and my team has added a few more panels you’ll want to add to your calendar. Make sure to check out the agenda here: https://lnkd.in/emRf_u8M The sessions we have planned are going to contribute greatly to the larger conversations going on about outlooks on fundraising, valuations, and M&A over the next 12-24 months. Dana Point is the place to be if you want to hear what trends are emerging in Medtech and Healthtech in 2024. I hope to see you there.

At #LSIEurope23, we had the privilege of hearing from the “Living Legend of Medicine”, Manny Villafa?a, during a special Lunch & Learn panel. Manny Villafa?a is a renowned Medtech entrepreneur, known for founding St. Jude Medical, where he developed the first bi-leaflet heart valve. Beyond this, Manny led seven companies to IPOs, and has a mile long track record. In this panel, he delves into his current venture, Medical 21, Inc., and shares the stories and insights from his remarkable career journey. Tune into the full panel, Lunch & Learn: Open Q&A With Manny Villafa?a, a “Living Legend of Medicine”, now available on our website and YouTube channel: https://lnkd.in/gijJu6Rk